
• Reported GAAP EPS of -$0.19 down -72.73% YoY • Reported revenue of $78.42M up 8.91% YoY • AngioDynamics raised its full year FY 2026 guidance for net sales to $313.5M and Adjusted EBITDA to $10M. AngioDynamics expects Med Tech net sales growth of 15%-17% and anticipates slightly negative cash flow for FY26 due to inventory build.
Bullish
AngioDynamics achieved strong Med Tech segment growth and standout performance from its mechanical thrombectomy and Auryon portfolios. The company also reported improved adjusted EBITDA and maintains a debt-free balance sheet.
Bearish
AngioDynamics experienced Q3 gross margin compression due to tariffs and inflation, recorded a GAAP net loss, and anticipates slightly negative FY26 cash flow from inventory build.